Paul Francis Olivier te Boekhorst, President and CEO of ImmuCell Corporation, filed a Form 4 on November 13, 2026, disclosing the exercise of 16,393 incentive stock options in Common Stock on November 12, 2026.
Key Highlights
- Transaction: te Boekhorst exercised 16,393 incentive stock options (transaction code M) on November 12, 2026 at an exercise price of $6.10 per share.
- Shares acquired: 16,393 shares of Common Stock, par value $.10 per share, were acquired as a result of the exercise.
- Post-transaction ownership: Following the transaction, te Boekhorst directly beneficially owns 34,131 shares of Common Stock.
- Remaining options: 57,884 incentive stock options remain subject to the option following the reported exercise, held directly.
- Ownership correction: The filing notes that total beneficial ownership shown reflects a correction to an amount previously reported on June 22, 2026, which overstated total ownership by 47 shares.
- Option vesting: According to the filing, the stock option vests in three annual installments of 24.759 shares on the first, second, and third anniversaries of the November 7, 2026 grant date, with the first installment vesting on November 7, 2026.
ImmuCell CEO Reports Option Exercise and Beneficial Ownership Correction
According to the Form 4 filed with the SEC on November 13, 2026, Paul Francis Olivier te Boekhorst, who serves as President and CEO and is also listed as a Director of ImmuCell Corp /DE/ (NASDAQ:ICCC), reported the acquisition of 16,393 shares of Common Stock through the exercise of incentive stock options on November 12, 2026. The exercise price of the derivative security was $6.10, and the filing records a price of $0 for the derivative security itself.
The filing discloses that the exercised options were part of a grant dated November 7, 2026, with an expiration date of November 7, 2035. The options vest in three annual installments of 24.759 shares on each of the first, second, and third anniversaries of the grant date. The filing states that the first installment vested on November 7, 2026. Following the exercise, 57,884 incentive stock options remain subject to the option, held directly by te Boekhorst.
The filing also includes a correction to previously reported ownership. As noted in the explanation of responses, total beneficial ownership of 34,131 shares of Common Stock shown in the filing "reflects a correction in the amount previously reported June 22, 2026 on Form 4 (which correctly reported the number of shares purchases but overstated total ownership by 47 shares)." The Form 4 was signed by Timothy C. Fiori as attorney-in-fact on November 13, 2026.
What Was Disclosed
te Boekhorst, President and CEO of ImmuCell Corp /DE/, disclosed the exercise of 16,393 incentive stock options at $6.10 on November 12, 2026, resulting in direct beneficial ownership of 34,131 common shares, along with a correction to a June 2026 ownership overstatement of 47 shares.





Please wait processing your request...